11/17 Taiwan BIO Weekly
2025-11-17 |
| Taiwan BIO Weekly |
| Lifesaving Science: Interview with TaiMed Biologics CEO, Jimmy Chang 14 November, 2025 Established in Taiwan, TaiMed Biologics is home to groundbreaking work that stretches beyond the traditional boundaries of medicine. Over the course of its 18-year history, the company has firmly established itself as a pioneering biopharmaceutical developer and manufacturer, with the results to back it up. "We successfully commercialised the first and only antibody-based molecule for HIV therapy," declares CEO Jimmy Chang. "It has been a real gamechanger for patients." More... |
| Taiwan's EirGenix partners with Sandoz for breast cancer biosimilar in $152 M deal 13 November, 2025 Taiwan-based EirGenix Inc. has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG for the commercialisation of its independently developed breast cancer biosimilar, EG1206A (Pertuzumab Biosimilar to Roche Perjeta), covering all territories except Taiwan, Mainland China, Macau, South Korea, Mongolia, Brunei, Cambodia, Indonesia, Laos, Myanmar, the Philippines, and Japan. More... |
| Early-life ketone signaling may shape long-term metabolic health 12 November, 2025 In a major advance in metabolic research, scientists from National Taiwan University have discovered that ketone bodies produced naturally during the lactation period are not merely an alternative fuel, but act as powerful developmental signals that shape the body's long-term metabolic health. More... |
| Unicocell Biomed's therapy for knee osteoarthritis completes Phase III enrollment 12 November, 2025 Unicocell Biomed (TW: 6794) announced that its Phase III clinical trial of the allogeneic, adipose-derived mesenchymal stem cell therapy ELIXCYTE for knee osteoarthritis has reached a key milestone, successfully enrolling the final patient. The study will continue with a one-year follow-up before unblinding. The trial, approved by Taiwan's TFDA in February 2023 and the US FDA in March 2023, targets patients with unilateral or bilateral knee osteoarthritis classified as grade II-III. More... (in Chinese) |
| Tanvex BioPharma narrows Q1-Q3 losses, Q3 revenue hits record high, boosted by biosimilar drug launches 12 November, 2025 Tanvex BioPharma (TW: 6541) reported a net loss of NT$1.079 billion (LPS: 4.53) for the first three quarters. However, strong growth in biosimilar sales and CDMO operations drove Q3 revenue to a record NT$125 million, a more than 160% increase from the previous quarter, marking the company's strongest quarterly performance since its founding and narrowing overall losses. The boost was led by the biosimilar TX-01, launched in the US in September by partner Cipla, generating over NT$49 million in Q3 sales. CDMO revenue also rose nearly 50% quarter-over-quarter due to multiple ongoing projects. Tanvex expects Cipla to launch its own-branded products in Q4 to expand US market visibility, while partner Sandoz continues to increase market share in Canada. The company also reclassified manufacturing-related costs from R&D to CDMO operating costs to better reflect revenue structure. More... (in Chinese) |
| Senhwa Biosciences partners with CancerFree Biotech to accelerate new drug development 12 November, 2025 Senhwa Biosciences (TW: 6492) has announced a strategic partnership with CancerFree Biotech, which owns a globally-exclusive cancer drug testing platform. Through CancerFree's E.V.A. Select Tumor Avatar Drug Testing Platform, the two companies will identify patient groups most responsive to Senhwa's novel drugs CX-5461 and CX-4945, aiming to significantly improve clinical trial success rates, accelerate drug development, and enhance global competitiveness. Developed and transferred from Taipei Medical University, the E.V.A. Select platform represents a breakthrough innovation that requires only 20 cc of blood to isolate and culture tumor avatars from circulating tumor cells (CTCs). These avatars allow simultaneous testing of multiple anticancer drugs to determine optimal treatment strategies. The technology can now generate over 100 cancer models and has been tested in more than 1,500 patients, with preclinical pancreatic cancer testing showing nearly 80% accuracy, earning strong recognition from both medical and industry experts. More... (in Chinese) |
| Senhwa Biosciences partners with CancerFree Biotech to accelerate new drug development 12 November, 2025 Senhwa Biosciences (TW: 6492) has announced a strategic partnership with CancerFree Biotech, which owns a globally-exclusive cancer drug testing platform. Through CancerFree's E.V.A. Select Tumor Avatar Drug Testing Platform, the two companies will identify patient groups most responsive to Senhwa's novel drugs CX-5461 and CX-4945, aiming to significantly improve clinical trial success rates, accelerate drug development, and enhance global competitiveness. Developed and transferred from Taipei Medical University, the E.V.A. Select platform represents a breakthrough innovation that requires only 20 cc of blood to isolate and culture tumor avatars from circulating tumor cells (CTCs). These avatars allow simultaneous testing of multiple anticancer drugs to determine optimal treatment strategies. The technology can now generate over 100 cancer models and has been tested in more than 1,500 patients, with preclinical pancreatic cancer testing showing nearly 80% accuracy, earning strong recognition from both medical and industry experts. More... (in Chinese) |
| GLAC Biotech Wins Double Honors at the iSEE Global Innovation Awards Lactobacillus plantarum PL-02 Sets a New Benchmark for Functional Probiotics Press release 11 November, 2025 GLAC Biotech, a leading innovator in probiotics and postbiotics research, proudly announces another milestone on the global stage. Its flagship strain, Lactobacillus plantarum PL-02, has been honored with two major awards at the 7th iSEE Global Innovation Awards, recognizing its outstanding scientific validation and breakthrough applications in both brain health and sports nutrition. More... |
| Bora Pharmaceuticals strengthens its local manufacturing footprint in North America 11 November, 2025 Bora Pharmaceuticals (TW: 6472) reported October revenue of NT$1.716 billion, down 17.85% year-over-year due to exchange rate fluctuations, but its cumulative ten-month revenue rose 6.57% to NT$16.613 billion, reflecting steady growth. The company continues to expand its North American manufacturing footprint, with its Maryland injectable plant, equipped with advanced aseptic and automated filling capabilities, serving as a key revenue driver. As the US promotes pharmaceutical reshoring and supply chain localization, Bora is well positioned as one of the few Asian CDMO providers offering full injectable manufacturing services in the US, supporting its long-term growth momentum. More... (in Chinese) |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2026 (15-19 July, 2026) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |